Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
ID: 347437Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347437

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)." This funding initiative aims to support the development of innovative tools and technologies that address significant challenges in the study of kidney, urologic, and hematologic diseases, focusing on high-risk, high-reward research rather than traditional hypothesis-driven approaches. The NIH anticipates funding approximately 10 projects with a total budget of around $2 million annually, providing up to $275,000 over a two-year project period, with no cost-sharing requirement. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with applications due by January 7, 2025.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-119.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for the "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases" (R21 Clinical Trial Not Allowed). This grant aims to promote innovative tool and technology development addressing unique challenges in studying kidney, urologic, and hematologic diseases. The funding opportunity, announced on April 11, 2023, supports projects that pursue novel technological developments rather than traditional hypothesis-driven research. Projects should develop significant innovations applicable beyond the applicant's own laboratory and address unmet needs in the field. NIDDK anticipates funding approximately 10 projects with a total budget of around $2 million annually, providing up to $275,000 over a two-year project period. Eligible entities include higher education institutions, nonprofits, and for-profit organizations, with no requirement for cost-sharing. Applications will be rigorously evaluated based on significance, innovation, approach, and investigator qualifications. The completion of various registrations, including Grants.gov and eRA Commons, is essential prior to submission, emphasizing compliance with NIH policies. The focus of this grant opportunity highlights the NIH’s mission to foster high-risk, high-reward research that could significantly advance scientific understanding and healthcare outcomes related to kidney, urologic, and hematologic diseases.
    Similar Opportunities
    Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Institutional Network Award (U2C) to enhance training in kidney, urologic, and hematologic research. This funding opportunity aims to foster a collaborative environment by inviting institutions to submit a unified application that supports a cohort of trainees and early-career investigators, with a strong emphasis on partnerships among institutions within metropolitan areas. The initiative is crucial for reshaping research training and promoting scientific collaboration, ensuring that the next generation of researchers is equipped to address complex biomedical challenges. Applications will be accepted starting October 16, 2023, with a submission deadline of September 27, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Kidney Technology Development Research Education Program (R25), aimed at fostering educational initiatives that encourage diverse individuals to pursue careers in nephrology and kidney technology development. This program seeks applications from institutions proposing innovative educational activities, including hands-on research projects, multidisciplinary teamwork, and training in entrepreneurship and regulatory processes, with a focus on recruiting undergraduate, graduate, and medical students from engineering and quantitative backgrounds. With a total funding allocation of $300,000 for FY 2025 and FY 2026, applications are due by June 15, 2025, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-009.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation" (RFA-HL-23-014). This grant aims to support early-stage translational research focused on developing devices, diagnostics, and research tools for heart, lung, blood, and sleep (HLBS) diseases, with an emphasis on prototype testing, user feedback, and regulatory strategies. The total funding available is up to $6.3 million per year, and applicants are required to provide substantial evidence of unmet medical needs and preliminary data, along with a minimum cash match of 25% from non-federal sources. Applications are due by December 20, 2024, and further inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. More details can be found at the provided link: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-014.html.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in nonmalignant hematology. This program invites investigator-initiated R01 grant applications that focus on emerging topics such as blood cell development, the effects of aging on hematopoiesis, and metabolic influences on blood cell formation, with the goal of advancing the field of hematology. The total funding available for this initiative is approximately $2.15 million for fiscal year 2022, with an estimated 2-9 grants to be awarded, and applications must be submitted through Grants.gov by January 7, 2025. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAS-22-096.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) grant. This funding opportunity aims to support projects that address critical needs for clinical trial readiness in rare diseases, specifically by facilitating the development of biomarkers and clinical outcome measures essential for trial design. The initiative is particularly important for advancing research on diseases affecting fewer than 200,000 individuals in the U.S., enhancing the likelihood of successful clinical trials. Applicants can request up to $275,000 over two years, with a submission deadline of October 17, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html.
    KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 - Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) to support exceptional graduate students transitioning into postdoctoral roles focused on Kidney, Urology, or Hematology (KUH) research. This funding opportunity aims to recruit talented individuals from diverse fields such as engineering, data science, and genetics, while excluding those already engaged in KUH research. The program provides funding for up to two years for dissertation research (F99 phase) and four years of mentored postdoctoral training (K00 phase), with stipends, tuition, and allowances for living costs. Interested applicants must adhere to specific eligibility criteria and are encouraged to contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries. The application deadline is April 1, 2025, and further details can be found at the provided link: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-033.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.